Teicoplanin therapy in children: a review

Area of Science:

• Pediatric Pharmacology
• Infectious Diseases
• Antibiotic Therapy

Background:

• Teicoplanin use in pediatric populations is less established than in adults.
• Previous studies suggest lower doses may be insufficient for pediatric patients.
• Gram-positive infections remain a concern in pediatric care.

Purpose of the Study:

• To evaluate the efficacy and tolerability of teicoplanin in pediatric patients.
• To determine optimal dosing regimens for children and newborns.
• To assess teicoplanin's effectiveness against Gram-positive infections in this demographic.

Main Methods:

• Pharmacological studies in children aged 2-12 years.
• Administration of teicoplanin (3-10 mg/kg/day) alone or in combination.
• Treatment of neutropenic and non-neutropenic pediatric patients with febrile episodes and Gram-positive infections.

Main Results:

• Doses of 3-6 mg/kg/day were insufficient for effective trough serum levels in children.
• A daily dose of 10 mg/kg/day achieved adequate serum concentrations.
• Teicoplanin, alone or with beta-lactams/aminoglycosides, was effective in treating febrile episodes in neutropenic children.
• Teicoplanin demonstrated high efficacy and good tolerability in over 100 pediatric patients.

Conclusions:

• Higher daily doses of teicoplanin (10 mg/kg) are necessary for effective treatment in pediatric patients.
• Teicoplanin is a well-tolerated and effective option for Gram-positive infections in children and newborns.
• Further clinical trials are recommended to solidify these findings.